Drugs Blog

Type of Drug:

Gonadotropin; hormone that stimulates the ovaries.

How the Urofollitropin Products Works:

Sitmulates eggs in the ovaries to fully develop before ovulation.

Uses of the Urofollitropin:

Used with human chorionic gonadotropin (HCG) to induce ovulation.

Urofollitropin and HCG may be used to stimulate the development of multiple eggs in patients participating in assisted reproductive programs.

Before therapy: Women must have a thorough pelvic exam and testing of the endocrine glands. A cervical dilation and curettage (D and C) must he done before beginning therapy if there is abnormal uterine bleeding or other signs of endometriosis. The partner’s fertility potential must also ho evaluated by a doctor.

Ovarian enlargement: Mild to moderate uncomplicated ovarian enlargement, which may be accompanied by abdominal bloating or pain, occurs in approximately 20% of patients treated with urofollitropin and HCG. It usually regresses without treatment within 2 to 3 weeks. If significant ovarian enlargement occurs after ovulation, do not engage in sexual intercourse.

Pregnancy: Do not use during pregnancy. The risk of use in a pregnant women clearly outweighs any possible benefit.

Breastfeeding: It is not known if urofollitropin is excreted in breast milk. Consult your doctor before you begin breastfeeding.

Children: Not indicated for use in children.

Lab Tests: Lab tests may be required to monitor therapy. Tests include estradiol laves and ultrasongraphy.

Side Effects of The Urofollitropin:

Every drug is capable of producing side effects. Many patients experience no, or minor, side effects. The frequency and severity of side effects depend on many factors including dose, duration of therapy, and individual susceptibility. Possible side effects include:

Digestive Tract: Nausea; vomiting; diarrhea; stomach cramps.

Urinary and Reproductive Tract: Bloating; severe pelvic pain; bleeding into the pelvic area (hemoperitoneum); ovarian hyper stimulation syndrome (OHSS); vaginal bleeding; ovarian enlargement; ovarian cysts.

Skin: Rash, pain, swelling, or irritation at injection site; dry skin; hair loss; hives; itching; facial swelling.

Other: Headache; breast tenderness; pain; multiple births; hot flashes; enlarged abdomen; intra vascular thrombosis and embolism (blood clots in the legs or lungs, lung damage, stroke, death).

Guidelines for Use:

• Dosage is individualized. Use exactlyasprE3scribed.
• Do not stop taking or change the dose, unless instructed by.your doctor.
• Inject Bravelle subcutaneously(SC;beneath the skin) or intramuscularly’ leally (lM; into a muscle).inject Fertile SC.
• Visually inspect solution for discoloration or particles. Use immediately after reconstitution (mixing). Discard any unused portion.
• If a dose is missed, inject it as soon as possible. If several hours have passed or it is nearing time for the next dose, do not double the dose to catch up, unless instructed by your doctor. If more than one dose is missed or it is necessary to establish a new dosage schedule, contact your doctor or pharmacist.
• Discontinue use and contact your doctor immediately severe pelvic pain, bloating, nausea, vomiting, diarrhea, faculty breathing, or decreased urination.
• BeG must be given following urofollitropin when tests follicles are present (eg, changes in vaginal smear or cervicalnary estrogen test) .
• Qvulation is confirmed by testing for progesterone itlbasal temperature, change in cervical mucus).
• A couple should have intercourse daily, beginning on the day prior to HCG administration, until ovulation occurs. Take care to ensure insemination. However, intercourse should be prohibited in patients in whom significant ovarian enlargement occurs after ovulation.
• Monitor for signs of pregnancy. If pregnancy is suspected, contact your doctor.
• Multiple. pregnancy is possible and poses potential hazards.
• Lab tests may be required to monitor therapy. Be sure to keep appointments.
• Store refrigerated or $t room temperature (30. to 77 F). light.

Type of Drug:

Antidepressant; mood-elevating agent
How the Venlafaxie Product Works:

Venlafaxine inhibits neuronal uptake of serotonin and norepinephrine in the central nervous system, which is believed to combat depression and other behavioral disorders.
Uses of The Venlafaxie:

The treatment of depression. The extended-release form is also used to treat generalized anxiety disorder.

Pregnancy: Adequate studies have not been done in pregnant women. Use only if clearly needed and potential benefits to the mother outweigh the possible hazards to the fetus.

Breastfeeding: Venlafaxine appears the breast milk. A decision should be made to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Children: Safety and effectiveness in children younger than 18 years of age have not been established.
Drug Interactions:

Tell your doctor or pharmacist if you are taking or if you are planning to take any over-the-counter or prescription medications or dietary supplements with venlafaxine HCI. Doses of one or both drugs may need to be modified or a different drug may need to be prescribod. The following drugs and drug classes interact with venlafaxino HCl.

*

MAOls (eg, phenelzine)
* Sibutramine (Meridia)

Side Effects:

Every drug is capable of producing side effects. Many venlafaxine HCI users experience no or minor side effects. The frequency and severity of side effects depend on many factors including dose, duration of therapy, and individual susceptibility. Possible side effects include:

Circulatory System: Increased blood pressure; increased heart rate; decreased blood pressure upon rising; flushing.

Digestive Tract: Nausea; constipation; appetite loss; diarrhea; vomiting; indigestion; stomach pain; gas; difficulty swallowing; dry mouth;belching.

Nervous System: Drowsiness; sleeplessness; dizziness; nervousness; headache; vertigo (feeling of whirling motion); migraine; anxiety; tremor; abnormal dreams; abnormal skin sensations; agitation; confusion; impaired memory; depression; abnormal thinking; unstable emotions; lockjaw; twitching; depersonalization; decreased sex drive; muscle stiffness.

Respiratory System: Yawning; bronchitis; difficulty breathing; runny nose; cough.

Senses: Blurred vision; taste changes; ringing in the ears; dilated pupils; ear pain; vision changes.

Skin: Sweating; rash; itching; flushing.

Urinary and Reproductive Tract: Abnormal ejaculation or orgasm; impotence; impaired urination; urinary frequency; menstrual disorders; blood in the urine; painful or difficult urination; irregular bleeding between periods; inflammation of the vagina with itching or abnormal discharge; urinary retention.

Other: Weakness; infection; chills; chest pain; weight gain or loss; accidental injury; general body discomfort; neck pain; muscle pain; joint pain; swelling of hands or feet; unusual bruising.
Guidelines for Use:

*

Tablets - Usual adult starting dose is 75 mg/day, taken in 2 or 3 divided doses. Dosage may be gradually increased to achieve the desired effect.
*

Extended-release capsules - Usual adult starting dose is 75 mg/day taken as a single dose.
*

Take each dose with food.
*

Do not crush, chew, or dissolve extended-release capsules in water. Swallow extended-release capsules whole, with fluid.
*

If a dose is missed, take it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised to do so by your doctor. If several doses are missed or it is necessary to establish a new dosage schedule, con­tact your doctor or pharmacist. Use exactly as prescribed.
*

Do not change the dose or stop taking venlafaxine unless advised to do so by your doctor.
*

If venlafaxine therapy is discontinued, the dose should be gradually reduced over a 2-week period.
*

Smaller doses should be used in patients with moderate liver or kidney impairment.
*

Venlafaxine should not be used in combination with an MAOI, or within at least 14 days of discontinuing treatment with an MAOI. After stop­ping venlafaxine, at least 7 days should elapse before starting an MAOI.
*

Because any psychoactive drug may impair judgment, thinking, or motor skills, do not operate hazardous machinery, including automobiles, until you are reasonably certain that venlafaxine does not adversely affect your ability to engage in such activities.
*

Inform your doctor if you are pregnant, become pregnant, are planning to become pregnant, or if you are breastfeeding during therapy.
*

Notify your doctor if rash, hives, or other allergic reactions occur.
*

Blood pressure will be monitored during treatment.
*

Notify your doctor or pharmacist if you are taking other prescription drugs, over-the-counter drugs, or supplements.
*

Avoid alcohol use during venlafaxine therapy.
*

Store at room temperature (68 to 77°F). Keep container tightly closed.